T1	Participants 63 83	chronic hepatitis C:
T2	Participants 119 290	patients with chronic hepatitis C, advanced fibrosis and cirrhosis are associated with lower rates of sustained virologic response (SVR) to interferon (IFN)-based therapy.
T3	Participants 484 590	1,046 patients enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial.
T4	Participants 591 704	All patients had failed prior treatment with IFN or peginterferon +/- RBV and had Ishak fibrosis scores > or = 3.
T5	Participants 705 782	Four groups of patients with increasingly severe liver disease were compared:
T6	Participants 1669 1712	patients with advanced chronic hepatitis C.
T7	Participants 1778 1807	"difficult-to-cure" patients.
